OTCQB: LXXGF | TSX.V: LXG

  • Company
    • Our Leadership
      • Leadership Team
      • Board of Directors
      • Scientific Advisory Board
    • Join Our Team
    • News Releases
    • In the Media
    • Upcoming Events
  • Investors
    • Presentations
    • Financials
    • Share Structure
    • Stock Information
    • Investor Events
    • Investor Inquiries
  • Markets
    • Biologics Manufacturing
    • Veterinary Diagnostics
  • Products
    • MiQLab® System
    • Assay Panels
    • Request Product Information
    • I’d Like a Demonstration
  • Resources
  • Our Blog
  • Contact
    • Contact
    • Investor Inquiries
    • Support
    • Product Information
    • Subscribe for Updates
Dr. Jack Regan, CEO LexaGene and BioPub Investment Interview – January 26, 2022

Dr. Jack Regan, CEO LexaGene and BioPub Investment Interview – January 26, 2022

by LexaGene | Feb 1, 2022 | Veterinary Diagnostics

Dr. Jack Regan, CEO and Founder of LexaGene gives an update to BioPub Investment group on January 26, 2021.

The Impact of Antimicrobial Stewardship and Your Veterinary Practice

The Impact of Antimicrobial Stewardship and Your Veterinary Practice

by Joe Fillion | Feb 1, 2022 | Veterinary Diagnostics

Learn more about new FDA antimicrobial stewardship guidance impacts the world of veterinary medicine in the coming years and how LexaGene’s MiQLab™ offers a solution.

PCR Testing: The Gold Standard for Companion Animals

PCR Testing: The Gold Standard for Companion Animals

by Gail Winslow | Jan 20, 2022 | Veterinary Diagnostics

Learn more about the MiQLab solution offering in-clinic point-of-care veterinary diagnostic testing in ~2 hours addressing more than 50 percent of companion animal vet visits and increasing satisfaction.

There is Even a Black Friday for Buying Capital Equipment

There is Even a Black Friday for Buying Capital Equipment

by Joe Fillion | Jan 14, 2022 | Veterinary Diagnostics

LexaGene’s MiQLab has direct benefits for veterinary clinics. Using LexaGene’s proven point-of-care diagnostics for evidence-based treatment of common bacterial infections found in companion animals may also result in cost savings.

What the Heck is a Mycoplasma and Why Doesn’t Anyone Like Them?

What the Heck is a Mycoplasma and Why Doesn’t Anyone Like Them?

by Dr Diane Stewart | Nov 18, 2021 | Biologics Manufacturing

The global bioburden testing market for bio-pharma contamination is approximately $10B, with over 350M tests run annually. LexaGene provides early detection for mycoplasma, aiding in validating product quality for biopharmaceutical manufacturers.

« Older Entries

Press Releases

  • Survey Says Veterinarians Have an Appetite for In-Clinic Diagnostic Technology May 25, 2022
  • The Dawn of the Superbugs May 10, 2022
  • LexaGene offers North Shore Technology Council (NSTC) and Leadership Team at MassBio a tour of our Beverly Facility April 7, 2022
  • Bacterial Culture: Is It Time to Rethink the Gold Standard? March 28, 2022
  • Antimicrobial Resistance: The Human and Animal Connection March 17, 2022

Categories

  • Biologics Manufacturing
  • Biothreat Detection
  • Human Clinical Diagnostics
  • Investor Information
  • Product Information
  • Veterinary Diagnostics
  • Contact
  • Support
  • Privacy
  • Terms
  • Site Map

500 Cummings Ctr., Suite 4550 Beverly, MA 01915 USA
info@lexagene.com | 800.215.1824

Subscribe for Updates
  • Follow
  • Follow
  • Follow
  • Follow

©2022 LexaGene All Rights Reserved